EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Recurrent coronary events in a patient with persistently elevated lipoprotein(a) during LDL-C-lowering therapy: a five-year serial coronary angiographic observation

Dan Li, Xuewen Qi

Frontiers in Cardiovascular Medicine · 18.11.2026 · 13

DOI: 10.3389/fcvm.2026.2012944 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 18.11.2026. Verfasst von Dan Li und 1 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated lipoprotein(a) [Lp(a)] is an established causal risk factor for atherosclerotic cardiovascular disease and may contribute to residual risk. However, a single case cannot establish that Lp(a) caused recurrent events. Case presentation A man aged 65 years in 2026 with hypertension and type 2 diabetes experienced four coronary events between December 2021 and June 2026. Serial angiography documented severe first diagonal branch (D1) stenosis treated with a drug-coated balloon in 2021, total occlusion of the second obtuse marginal branch (OM2) treated with a drug-coated balloon in 2022, approximately 95% mid-right coronary artery (RCA) stenosis treated with a drug-eluting stent in 2023, and a new distal RCA occlusion causing inferior-posterior ST-segment elevation myocardial infarction (STEMI) in 2026. The previously implanted RCA stent remained patent during the 2026 event. Lp(a), measured by immunoturbidimetry at the same clinical laboratory, was 592, 899, 967, and 1,032 mg/L at the 2021, 2022, 2023, and June 2026 assessments, respectively, and 980 mg/L at stable follow-up in August 2026. LDL-C was 3.51 mmol/L in 2021, 1.14 mmol/L during the June 2026 STEMI, and 0.71 mmol/L at stable follow-up in August 2026. ApoB was not measured during the June 2026 admission.

Conclusion

This case documents recurrent coronary events in different territories alongside persistently marked Lp(a) elevation. Lp(a) may have contributed to residual risk, but prior LDL-C exposure, diabetes, hypertension, treatment intensity, adherence, and measurement variability are important alternative or additional explanations.

Zitieren

APA

Li, D., & Qi, X. (2026). Case Report: Recurrent coronary events in a patient with persistently elevated lipoprotein(a) during LDL-C-lowering therapy: a five-year serial coronary angiographic observation. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.2012944

Vancouver

Li D, Qi X. Case Report: Recurrent coronary events in a patient with persistently elevated lipoprotein(a) during LDL-C-lowering therapy: a five-year serial coronary angiographic observation. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.2012944

BibTeX
@article{Li2026,
  author = {Li, Dan and Qi, Xuewen},
  title = {Case Report: Recurrent coronary events in a patient with persistently elevated lipoprotein(a) during LDL-C-lowering therapy: a five-year serial coronary angiographic observation},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.2012944}
}
Kostenlos starten →